HPB P42 Investigating Factors Associated with Favourable Pathological Tumour Regression After Neoadjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma

Abstract Background Neoadjuvant chemotherapy (NAT) is increasingly used in the management of pancreatic ductal adenocarcinoma (PDAC). Pathological response tumour to NAT can be assessed using grading systems such as College American Pathologists (CAP) system, with favourable regression being associated improved survival. The aim study was investigate factors patients undergoing pancreatoduodenectomy (PD) for PDAC Methods Patients who received before resection at our institution between 2012 and 2020 were reviewed. Interactions chemotherapy, staging, carbohydrate antigen 19–9 (Ca19–9) levels, perioperative pathological (TRG) explored. Results 27 suitable inclusion a median follow-up 17.9 months. 7 (26%) had NAT. Demographic details initial staging similar groups. There significant difference change Ca19–9 levels from start end non-favourable TRG groups, significantly greater reduction observed group [median -1,862 U/mL (IQR: -7,028 -121U/mL)] compared unfavourable -194 (-635 -3.9 U/mL); p=0.011). no regime, number cycles or dose due adverse effects. time diagnosis surgery also similar. Conclusions In this small retrospective study, TRG, which has been Patient numbers are limited recent introduction pathology reporting guidelines so multicentre collaboration should encouraged identify more regression. Translational research may able other (e.g. gene expression)